Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › F/TAF

F/TAF

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of F/TAF

7 trials tracked of F/TAF: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 395 citations.

7Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 5 Phase 2 2
  1. Phase 3 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Completed · 395 cited
  2. Phase 3 Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF Completed · 165 cited
  3. Phase 3 Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC Completed · 160 cited
  4. Phase 3 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed Completed · 112 cited
  5. Phase 3 Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen Completed
  6. Phase 2 Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV Completed
Show 1 more trials
  1. Phase 2 Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
F/TAF PrEP shows similar HIV incidence to F/TDF in cisgender women but noninferiority not proven
Infectious Disease RCT
F/TAF PrEP shows similar HIV incidence to F/TDF in cisgender women but noninferiority not proven PrEP pill F/TAF shows similar HIV prevention as F/TDF in women
This RCT in 1380 predominantly cisgender women in East and South Africa compared daily oral F/TAF vs F/TDF for HIV PrEP over 6 months. HIV i…
A study in African women found that a newer PrEP pill (F/TAF) prevented HIV at similar rates to the standard pill (F/TDF), but the study was…
Jun 1, 2026